Phase 2 Study of NGM282 in Patients With Type 2 Diabetes

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Activity of NGM282 Administered for 28 Days to Patients With Type 2 Diabetes Mellitus

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01943045

Enrollment

Registered

2013-09-16

Start date

2013-09-30

Completion date

2014-09-30

Last updated

2015-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Type 2 Diabetes.

Interventions

BIOLOGICALNGM282

OTHERPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Males or females, between 18 and 70 years of age, inclusive * BMI range of 24-40 kg/m2, inclusive * No active coronary artery disease * Resting heart rate in the range of 40-100 bpm

Exclusion criteria

* Diagnosis of Type 1 diabetes * History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance

Design outcomes

Primary

Measure	Time frame
Fasting Plasma Glucose	28 days

Secondary

Measure	Time frame
HbA1c	28 days
Lipids	28 days

Countries

Australia, New Zealand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026